Incyte Corp
INCYHealthcare|Biotechnology|USA
$93.59
-1.27 (-1.34%)
DCF (FCF)
$55.64
Tangible Book
$24.78
Graham Number
$61.53
Earnings Power
$50.38
Upcoming Data Readouts (92)
Oct 2026
Est. completion
P3Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
NCT06958211n=550
Oct 2026
Est. completion
P3Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225n=550
Oct 2026
Est. completion
P3Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516952n=330
Oct 2026
Est. completion
P3Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965n=330
Dec 2026
Est. completion
P2TNBC - Triple-Negative Breast Cancer
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
NCT05491226n=35
Dec 2026
Est. completion
P1Hidradenitis Suppurativa
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575n=24
Dec 2026
Est. completion
P3Hidradenitis Suppurativa (HS)
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999n=617
Dec 2026
Est. completion
P1Acute Myeloid Leukemia
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
NCT04659616n=32
Dec 2026
Est. completion
P1P2Non Hodgkins Lymphoma
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
NCT04661007n=72
Dec 2026
Est. completion
P2Advanced Pancreatic Carcinoma
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
NCT06906562n=40
Dec 2026
Est. completion
P2Grade 3b Follicular Lymphoma
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
NCT05890352n=227
Dec 2026
Est. completion
Early P1Lymphoma, B-Cell
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
NCT04161248n=18
Dec 2026
Est. completion
P2T-cell Lymphoma
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
NCT07356245n=44
Jan 2027
Est. completion
P2Large B-cell Lymphoma
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
NCT06760156n=28
Jan 2027
Est. completion
P1Chronic Lymphocytic Leukemia
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NCT05943496n=27
Jan 2027
Est. completion
P2Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
NCT06300528n=27
Jan 2027
Est. completion
P1Myelofibrosis Due to and Following Polycythemia Vera
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
NCT05714072n=18
Jan 2027
Est. completion
P2Splenomegaly
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
NCT06345495n=30
Jan 2027
Est. completion
P1Solid Tumors
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06179160n=710
Jan 2027
Est. completion
P1Solid Tumors
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324n=408
Awaiting Results (32)
Trials past primary completion date but still active — data readout may be imminent.
Sep 2026
P2P3
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT03117751Sep 2026
P2
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
NCT05888844Sep 2026
P3
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092Jul 2026
P2
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
NCT05879822Jun 2026
P2
A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib
NCT04640025Jun 2026
P1
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
NCT02494882May 2026
P1P2
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
NCT06873789Apr 2026
P2
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
NCT04463771